PRQR

1.81

5.85% 0.10

Handel nachbörslich: 1.83 0.02 +1.10%

Proqr Therapeutics N V (PRQR)

Überblick Nachrichten Preisverlauf Optionskette Forum Prognose

Schlusskurs vom Vortag:

$1.71

Offen:

$1.85

24-Stunden-Volumen:

888.25K

Relative Volume:

2.07

Marktkapitalisierung:

$190.70M

Einnahmen:

$17.91M

Nettoeinkommen (Verlust:

$-47.66M

KGV:

-3.9815

EPS:

-0.4546

Netto-Cashflow:

$-62.63M

1W Leistung:

+19.87%

1M Leistung:

+1.69%

6M Leistung:

-23.31%

1J Leistung:

+53.39%

1-Tages-Spanne:

$1.675

$1.875

1-Wochen-Bereich:

$1.51

$1.875

52-Wochen-Spanne:

$1.07

$3.10

Proqr Therapeutics N V Stock (PRQR) Company Profile

Firmenname

Proqr Therapeutics N V

Sektor

Healthcare (1116)

Branche

Biotechnology (624)

Telefon

Adresse

Mitarbeiter

187

Twitter

@proqr

Nächster Verdiensttermin

2026-03-12

Neueste SEC-Einreichungen

PRQR's Discussions on Twitter

Compare PRQR vs VRTX, REGN, ARGX, ALNY, INSM

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
PRQR Proqr Therapeutics N V	1.81	180.17M	17.91M	-47.66M	-62.63M	-0.4546
VRTX Vertex Pharmaceuticals Inc	434.30	111.45B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	763.04	80.54B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	748.25	46.32B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	330.34	42.29B	3.71B	313.75M	465.38M	2.2571
INSM Insmed Inc	163.81	35.01B	606.42M	-1.28B	-997.58M	-6.403

Proqr Therapeutics N V Stock (PRQR) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2026-03-12	Fortgesetzt	Oppenheimer	Outperform
2025-04-29	Fortgesetzt	Cantor Fitzgerald	Overweight
2025-04-29	Eingeleitet	Evercore ISI	Outperform
2025-03-10	Hochstufung	Citigroup	Neutral → Buy
2025-01-10	Eingeleitet	Oppenheimer	Outperform
2024-10-29	Hochstufung	Raymond James	Outperform → Strong Buy
2023-11-08	Hochstufung	Chardan Capital Markets	Neutral → Buy
2023-03-30	Hochstufung	JMP Securities	Mkt Perform → Mkt Outperform
2022-12-22	Hochstufung	Cantor Fitzgerald	Neutral → Overweight
2022-02-14	Herabstufung	Citigroup	Buy → Neutral
2022-02-11	Herabstufung	Raymond James	Strong Buy → Mkt Perform
2022-02-11	Herabstufung	Stifel	Buy → Hold
2022-02-01	Eingeleitet	Raymond James	Strong Buy
2021-05-03	Eingeleitet	Stifel	Buy
2021-03-25	Bestätigt	Citigroup	Buy
2020-11-03	Fortgesetzt	Cantor Fitzgerald	Overweight
2019-03-12	Bestätigt	Chardan Capital Markets	Buy
2018-12-19	Eingeleitet	RBC Capital Mkts	Outperform
2018-11-15	Eingeleitet	Citigroup	Buy
2018-09-19	Eingeleitet	Evercore ISI	Outperform
2017-09-26	Bestätigt	JMP Securities	Mkt Outperform
2016-06-20	Eingeleitet	Chardan Capital Markets	Neutral
2014-10-15	Eingeleitet	Deutsche Bank	Buy
2014-10-13	Eingeleitet	H.C. Wainwright	Buy

Alle ansehen

Proqr Therapeutics N V Aktie (PRQR) Neueste Nachrichten

Apr 04, 2026

ProQR Therapeutics N.V. (NASDAQ:PRQR) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat

Apr 01, 2026

What analysts say about ProQR Therapeutics NV stockWeekly Trend Recap & Expert Verified Movement Alerts - baoquankhu1.vn

Apr 01, 2026

Mar 31, 2026

US Market Recap: Can ProQR Therapeutics NV benefit from deglobalization2026 Summary & Detailed Earnings Play Alerts - baoquankhu1.vn

Mar 31, 2026

Mar 30, 2026

Aug Reactions: Can ProQR Therapeutics NV weather a recessionMarket Growth Report & AI Forecasted Entry and Exit Points - baoquankhu1.vn

Mar 30, 2026

Mar 27, 2026

PRQR SEC FilingsProqr Therapeuti 10-K, 10-Q, 8-K Forms - Stock Titan

Mar 27, 2026

Mar 26, 2026

Retail Trends: Will ProQR Therapeutics NV stock recover after earningsIPO Watch & Safe Swing Trade Setup Alerts - baoquankhu1.vn

Mar 26, 2026

ProQR Sets April 8 Virtual Investor Event to Spotlight Axiomer RNA Editing Pipeline - The Globe and Mail

Mar 26, 2026

Price Action: Is ProQR Therapeutics NV attractive for institutional investors2026 Pullback Review & Risk Adjusted Swing Trade Ideas - baoquankhu1.vn

Mar 26, 2026

Mar 25, 2026

Growing Optimism About ProQR Therapeutics (PRQR)’s RNA Editing Platform and Future Clinical Catalysts - Yahoo Finance

Mar 25, 2026

ProQR (PRQR) schedules April 8 virtual event on Axiomer RNA pipeline - Stock Titan

Mar 25, 2026

ProQR to Host Virtual Investor and Analyst Event Highlighting Pipeline on April 8, 2026 - globenewswire.com

Mar 25, 2026

Ahead of AX-0810 data, ProQR plans April 8 pipeline webcast - Stock Titan

Mar 25, 2026

Mar 20, 2026

Evercore ISI Group Initiates Coverage of ProQR Therapeutics N.V. (PRQR) with Outperform Recommendation - MSN

Mar 20, 2026

Mar 19, 2026

Research Analysts Set Expectations for PRQR Q2 Earnings - Defense World

Mar 19, 2026

Mar 18, 2026

ProQR (NASDAQ: PRQR) director details substantial share and long-dated option holdings - Stock Titan

Mar 18, 2026

ProQR (PRQR) CSO details sizeable option grants and share stake - Stock Titan

Mar 18, 2026

Director Maier details ProQR (PRQR) share option grants and vesting - Stock Titan

Mar 18, 2026

ProQR (PRQR) director Alison Lawton details multiple option grants - Stock Titan

Mar 18, 2026

ProQR (PRQR) CFO discloses 1,000,000-share option position in Form 3 - Stock Titan

Mar 18, 2026

Theresa Heggie (PRQR) details option and share holdings in Form 3 - Stock Titan

Mar 18, 2026